Sutro Biopharma (STRO) Short term Debt (2017 - 2023)

Sutro Biopharma has reported Short term Debt for 6 years, with the latest figure at $4.1 million in Q4 2023.

• Quarterly Short term Debt fell 67.51% year-over-year to $4.1 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4.1 million (down 67.51% YoY) and the FY2023 annual result came in at $4.1 million, down 67.51% from the prior year.
• Short term Debt retreated to $4.1 million in Q4 2023 per STRO's latest filing, from $7.1 million in the prior quarter.
• Over five years, Short term Debt peaked at $13.2 million in Q1 2023 and troughed at $1.0 million in Q4 2019.
• A 4-year average of $8.1 million and a median of $7.1 million in 2023 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2019 and 2022: Short term Debt plunged 78.83% in 2019, then soared 300.0% in 2022.
• Over 4 years, Short term Debt stood at $1.0 million in 2019, then soared by 837.5% to $9.4 million in 2021, then jumped by 33.33% to $12.5 million in 2022, then plunged by 67.51% to $4.1 million in 2023.
• According to Business Quant data, Short term Debt over the past three periods registered $4.1 million, $7.1 million, and $10.2 million for Q4 2023, Q3 2023, and Q2 2023 respectively.